Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127147451 | 12714745 | 1 | I | 2016 | 20160621 | 20160905 | 20160905 | PER | US-JNJFOC-20160619970 | JANSSEN | 0.00 | A | F | Y | 105.24000 | KG | 20160905 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127147451 | 12714745 | 1 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 294ML PER HOUR OVER 67 MINUTES | N | 0 | 88 | MG | LIPOSOME INJECTION | ||||||
127147451 | 12714745 | 2 | PS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 1MG PER MINUTE FOR 15 MINUTES | N | 50718 | 15 | MG | LIPOSOME INJECTION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127147451 | 12714745 | 1 | Breast cancer metastatic |
127147451 | 12714745 | 2 | Breast cancer metastatic |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127147451 | 12714745 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127147451 | 12714745 | Breast cancer metastatic |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127147451 | 12714745 | 1 | 20160607 | 0 | ||
127147451 | 12714745 | 2 | 20160510 | 20160510 | 0 |